Administration

行政

基本信息

批准号：
10401879
负责人：
Ruth Margrit Ruprecht
金额：
$ 14.93万
依托单位：
UNIVERSITY OF LOUISIANA AT LAFAYETTE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-05-01 至 2024-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10401879
关键词：
Achievement Acquired Immunodeficiency Syndrome Address Area Biomedical Research Biotechnology Budgets Businesses Cold Chains Collaborations Communication Country Europe European Goals HIV vaccine HIV-1 Image Immunology Individual Infectious Agent Institutes Institution Intellectual Property Lead Louisiana Macaca mulatta Manuscripts Medicine Modeling Monitor Mucous Membrane National Institute of Allergy and Infectious Disease Needles Oral Positron-Emission Tomography Primates Protocols documentation Publications Radionuclide Imaging Reagent Reporting Research Research Institute Research Personnel Resources Sampling Science Scientist Ships Site Visit Solid Switzerland Technology Texas Time Training Travel United States National Institutes of Health Universities Vaccines Viral Pathogenesis Virginia Virosomes Visit Washington base capsule data dissemination design dosage experimental study ileum innovation manufacturing process material transfer agreement meetings nonhuman primate novel vaccines payment prevent programs simian human immunodeficiency virus skills translational goal vaccine delivery vaccine formulation vaccine immunogenicity vaccine platform whole body imaging

项目摘要

The overall objective of administrative Core A is to provide this multi-PI, multi-institutional U19 IPCAVD Project the opportunity to interact synergistically by facilitating the communication among the Project Leaders and all participating scientists. Core A will also serve as liaison between Research Administration at the contact institution, the Texas Biomedical Research Institute (TxBiomed), all the affiliated institutions both in the US and in Europe, and NIAD representatives. The network of partnering scientists includes researchers in Texas, Louisiana, Georgia and several countries in Europe; the major partner is Mymetics in Switzerland. The innovative biotech company has developed gp41-based virosomes into to a novel vaccine platform that is cold-chain independent and can be administered mucosally without needles. The Specific Aims of Core A are to: 1. Provide administrative support and facilitate the collaboration among Projects 1 and 2 and the various subcontract/subaward leaders and partners. This will include the exchange of information, reagents, and material transfer agreements. 2. Set priorities, monitor progress and jointly make go/no-go decisions. This will be achieved with input from the External Scientific Advisory Board (ESAB) and the NIAID IPCAVD Program Officer. 3. Assist in the design of experiments in rhesus macaques (RMs), protocol design and submission, and exchange of samples between the New Iberia Research Center (NIRC), where the primate studies will be conducted, and TxBiomed. 4. Provide statistical support for all IPCAVD scientists through the participation of Dr. Sarah Ratcliffe through a subaward with the University of Virginia (UVA). 5. Provide financial oversight and assure prompt payment of bills as well as the timely achievement of the experimental goals within budget limits. 6. Organize the yearly NIH Site Visit and the External Scientific Advisory Board (ESAB) meeting in the Washington, D.C. area, as well as individual visits between Drs. Ruprecht, Villinger, Santangelo and Fleury. 7. Address intellectual property (IP) issues fairly, timely, and equitably. 8. Facilitate the submission of reports, dissemination of data at meetings, and publication of manuscripts. To meet the goals of this translational, highly interactive U19 Research Program, the Core A Leader/Contact PI depends on the trained professionals with excellent organization skills as well as basic understanding of science and medicine to make this U19 network of scientists successful.

行政核心A的总体目标是提供此多PI，多机构的U19 IPCAVD项目通过促进项目领导者和所有人之间的沟通来协同互动的机会参与科学家。核心A还将作为联系人的研究管理德克萨斯州生物医学研究所（TXBIOMED）机构，美国和在欧洲和NIAD代表。合作科学家的网络包括德克萨斯州的研究人员路易斯安那州，佐治亚州和欧洲几个国家；主要合作伙伴是瑞士的Mymetics。创新 Biotech Company已将基于GP41的病毒体开发到一个新型的疫苗平台，该平台是冷链独立，可以无针施用粘膜。核心A的具体目的是： 1。提供行政支持并促进项目1和2之间的协作以及各种分包/子领导者和合作伙伴。这将包括信息交换，试剂和物质转移协议。 2。设定优先级，监控进度并共同做出/不进行决定。这将通过输入来实现来自外部科学顾问委员会（ESAB）和NIAID IPCAVD计划官员。 3。协助设计恒河猕猴（RMS），协议设计和提交的实验以及新伊比利亚研究中心（NIRC）之间的样品交换，灵长类动物研究将在其中进行，并进行txbiom。 4。通过Sarah Ratcliffe博士的参与为所有IPCAVD科学家提供统计支持通过弗吉尼亚大学（UVA）的子宣告。 5。提供财务监督并确保及时支付账单以及及时的成就预算限制内的实验目标。 6.在The The The The Moly年度NIH现场访问和外部科学顾问委员会（ESAB）会议上华盛顿特区地区以及博士之间的个人访问。 Ruprecht，Villinger，Santangelo和弗勒里。 7。公平，及时和公平地解决知识产权（IP）问题。 8。促进报告的提交，会议上的数据传播以及手稿的发布。为了满足这个翻译高度互动的U19研究计划的目标，核心A领导者/联系PI 取决于训练有素的专业人士，具有出色的组织技能以及对科学的基本理解和药物使这个U19科学家网络成功。